Skip to main content
OpenTrials
Completed

NCT Number: NCT03799900

Assessment of Abuse Potential of Rapastinel in Humans

Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the abuse potential of single doses of rapastinel as compared with ketamine, a NMDAR antagonist that is a Schedule III dissociative anesthetic, and placebo in recreational polydrug users.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Vince and Associates Clinical Research Inc

Overland Park, Kansas, 66212, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant must be a current recreational polydrug user
  • Have a supine systolic blood pressure (BP) ≥ 95 mm Hg and ≤ 145 mg Hg, or supine diastolic BP ≥ 50 mm Hg and ≤ 90 mm Hg at the Screening Visit.
  • Have negative test results for benzoylecgonine (cocaine), methadone, barbiturates, amphetamines, benzodiazepines, alcohol, oxycodone and other opioids, and phencyclidine at any admission
  • Able, as assessed by the investigator, and willing to follow study instructions and likely to complete all required study visits

Exclusion criteria

  • Evidence of drug or alcohol dependence (excluding nicotine and caffeine) within the past 2 years
  • Suicidal risk based on the opinion of the principal investigator (or appropriately trained designee)
  • History of violent or psychotic behavior when taking psychedelic drugs, or unwilling to take a drug that might alter perception in a controlled setting
  • Have taken or require concomitant treatment with any CNS depressants, or cannot safely discontinue these medications within 14 days (or 5 half-lives, whichever is longer) before study treatment administration
  • Previously participated in an investigational study of rapastinel.
  • Participation in any other clinical investigation using an experimental drug within 30 days, 5 half-lives or twice the duration of the biological effect of the study treatment (whichever is longer), prior to study treatment administration or is concurrently enrolled in any clinical trial, judged not to be scientifically or medically compatible with this study
  • Consumption of alcohol within 72 hours before administration of study treatment
  • Breastfeeding
  • Unable to refrain from consuming caffeine or xanthine-containing compounds such as tea, coffee, soft drinks, energy sports drinks or chocolate (more than 48 oz/day) from 48 hours before administration of study treatment.
  • Have consumed dietary supplements or other foods or beverages that may affect various drug metabolizing enzymes and transporters (eg, grapefruit, grapefruit juice, grapefruit-containing beverages), vegetables from the mustard green family (eg, kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard), and charbroiled meats within 14 days prior to dosing or unable to refrain from consumption during the study.
  • The ability to tolerate IV ketamine as judged by the Investigator, based on available safety data, as well as pharmacodynamic data.

Treatment and study plan

Rapastinel

Drug

During the Treatment Phase in Part 2, participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.

ketamine

Drug

Part 1

Part 2, Qualification Phase:

Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner

Part 2, Treatment Phase:

Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.

Placebo

Drug

Part 1

Part 2, Qualification Phase:

Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner

Part 2, Treatment Phase:

Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.

Primary outcomes

  1. Maximum effect (Emax) for "At this Moment" Drug Liking visual analog scale (VAS).

    Time frame: Treatment Phase: Pre-dose and up to 24 hours post-dose

    The drug liking VAS measures the participant's liking for the drug and is scored from 0 to 100, with 0 reflecting "Strong disliking" and 100 reflecting "Strong liking".

Secondary outcomes

  1. Maximum effect (Emax)

    Time frame: Treatment Phase: Pre-dose and up to 24 hours post-dose

  2. Minimum effect (Emin)

    Time frame: Treatment Phase: Pre-dose and up to 24 hours post-dose

  3. Time to Emax (TEmax)

    Time frame: Treatment Phase: Pre-dose and up to 24 hours post-dose

  4. Time to Emin (TEmin)

    Time frame: Treatment Phase: Pre-dose and up to 24 hours post-dose

  5. Time averaged area under the effect curve (TA_AUE)

    Time frame: Treatment Phase: Hour 0 and up to 24 Hours post-dose

  6. Maximum plasma drug concentration (Cmax)

    Time frame: Treatment Phase: Pre-dose and up to 24 hours post-dose

  7. Area under the plasma concentration versus time curve from time 0 to the last quantifiable concentration (AUClast)

    Time frame: Treatment Phase: Pre-dose and up to 24 hours post-dose

  8. Adverse events

    Time frame: Part 1: 6 weeks, Part 2: 9 weeks

  9. Proportion of abnormal electrocardiograms

    Time frame: Part 1: 6 weeks, Part 2: 9 weeks

  10. Columbia-Suicide Severity Rating Scale

    Time frame: Part 1: 6 weeks, Part 2: 9 weeks

    The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 (least severe) to 5 (most severe).

Sponsors and collaborators

Lead sponsor

Naurex, Inc, an affiliate of Allergan plc

Industry

Registry information

Official study title

A Two-part, Single-dose, Randomized, Double-blind, Placebo and Active-Controlled Crossover Study to Evaluate the Abuse Potential of Rapastinel in Healthy, Non-dependent, Adult Recreational Polydrug Users

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Jan 10, 2019
Registry last updated
May 16, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.